RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKWELL MEDICAL, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.49+0.06 (+0.81%)
Close on Oct 19, 2026
- Market cap
- $29.65M
- P/E (TTM)
- –
- Dividend yield
- –
ROCKWELL MEDICAL, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentrate Product | – | – | – | $75.24M | $87.62M | $97.37M | $101.44M | $98.87M | $92.14M | $84.34M | $81.27M | $78.37M | – | – |
| Drug Revenues | – | – | – | $337.00K | $348.00K | $360.00K | $46.00K | $45.00K | $2.23M | $2.28M | $2.34M | $2.46M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $59.43M | $58.49M | $60.36M | $66.32M | $78.74M | $87.76M | $92.26M | $90.94M | $84.43M | $77.35M | $74.34M | $71.23M | 85.6% | -24.5% |
| Rest of World | $9.96M | $9.20M | $8.90M | $9.26M | $9.23M | $9.97M | $9.23M | $7.98M | $9.94M | $9.28M | $9.27M | $9.60M | 14.4% | +8.0% |
From the segment and revenue-disaggregation notes of Rockwell Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.